DexCom (NASDAQ:DXCM) Insider Sells $1,926,648.00 in Stock

DexCom, Inc. (NASDAQ:DXCM) insider Kevin Sayer sold 26,759 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the transaction, the insider directly owned 382,482 shares of the company’s stock, valued at approximately $27,538,704. This trade represents a 6.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Trading Up 3.0%

Shares of DXCM opened at $72.34 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. The firm has a 50 day simple moving average of $64.05 and a 200-day simple moving average of $66.39. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $89.98. The stock has a market cap of $27.91 billion, a price-to-earnings ratio of 30.91, a price-to-earnings-growth ratio of 1.16 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same period last year, the company posted $0.32 EPS. The company’s revenue was up 15.0% on a year-over-year basis. Equities analysts forecast that DexCom, Inc. will post 2.57 EPS for the current fiscal year.

Institutional Trading of DexCom

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Avidity Partners Management LP purchased a new stake in DexCom in the 1st quarter worth approximately $5,652,000. Glenmede Trust Co. NA grew its stake in shares of DexCom by 36.7% during the 1st quarter. Glenmede Trust Co. NA now owns 394,751 shares of the medical device company’s stock valued at $24,790,000 after buying an additional 105,928 shares during the period. Wellington Grp LLC grew its stake in shares of DexCom by 778.7% during the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock valued at $34,000 after buying an additional 475 shares during the period. Janus Henderson Group PLC grew its stake in shares of DexCom by 32.3% during the 1st quarter. Janus Henderson Group PLC now owns 2,644,539 shares of the medical device company’s stock valued at $166,077,000 after buying an additional 645,534 shares during the period. Finally, Centaurus Financial Inc. purchased a new stake in shares of DexCom during the 1st quarter valued at $943,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Mizuho set a $75.00 target price on shares of DexCom in a research note on Friday, May 1st. Citigroup reissued a “buy” rating and issued a $84.00 target price (up from $79.00) on shares of DexCom in a research note on Thursday. Bank of America lowered their target price on shares of DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Benchmark began coverage on shares of DexCom in a research note on Monday, May 11th. They issued a “buy” rating and a $77.00 target price for the company. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of DexCom in a research note on Thursday, February 5th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $82.42.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.